MERSANA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.73 USD | +5.81% |
|
+0.74% | +17.67% |
| May. 09 | Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
| May. 09 | Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M | MT |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Mersana Therapeut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Calendar
2024-06-11
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.73
USD
Average target price
6.375
USD
Spread / Average Target
+133.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.67% | 316M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- MRSN Stock
- News Mersana Therapeutics, Inc.
- Transcript : Mersana Therapeutics, Inc., Q4 2020 Earnings Call, Feb 26, 2021